Fresh hope in advanced breast cancer...

LENTARON (4-hydroxyandrostenedione; 4-OHA) is a selective, fortightly injectable aromatase inhibitor which marks an important development in the hormonal treatment of advanced breast cancer. With its unique and selective mode of action, LENTARON is not only effective in preventing disease progression, but it also has a prolonged duration of response and a low incidence of side-effects.¹

So for patients who have relapsed on tamoxifen, offer LENTARON and you’ll offer renewed hope.

For a free LENTARON information pack, phone (0403) 272827 and ask for the Medical Information Department.